CFO
BBIO icon

CVA Family Office’s BridgeBio Pharma BBIO Stock Holding History

CVA Family Office’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Buy
205
+59
+40% +$4.13K ﹤0.01% 896
2026
Q1 		$10.8K Buy
+146
New +$10.6K ﹤0.01% 964

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

CVA Family Office's BBIO Position: Q2 2026 in Review

CVA Family Office increased its BridgeBio Pharma (BBIO) stake by 40% in Q2 2026, buying an estimated $4.13K and bringing the position to 205 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #896.

CVA Family Office first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • CVA Family Office held 205 shares of BridgeBio Pharma worth $15.3K as of Q2 2026.
  • CVA Family Office bought 59 BridgeBio Pharma shares in Q2 2026, an estimated $4.13K.
  • BridgeBio Pharma made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #896 holding.
  • CVA Family Office first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.